UBS downgraded GSK to Neutral from Buy with a price target of 1,580 GBp, down from 2,040 GBp. The analyst cites Arexvy uncertainty, U.S. Shingrix weakness and continued Zantac litigation overhang for the downgrade. GSK’s valuation is attractive but the stock has no clear catalysts, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- FDA to evaluate potential risk of neural tube birth defects with dolutegravir
- GSK Acquires Key Vaccine Rights from Partner CureVac in €1.45B Deal
- CureVac jumps 21% to $4.06 after GSK expands licensing deal
- GSK, CureVac restructure existing collaboration into new licensing agreement
- GSK price target raised to $53 from $52.50 at Jefferies